The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•8 April 2026•

1 min read

BD Secures EU Approval for Innovative Adjustable Liver Stent

Key Facts

1BD (Becton, Dickinson and Company) received CE Mark approval for its Liverty™ TIPS Stent Graft.

2The stent features an adjustable diameter from 6 to 10 mm to personalize therapy for cirrhosis patients.

Version History

1 additional source confirmed this story

Becton, Dickinson and Company (BD) has officially secured CE Mark approval for its Liverty™ TIPS Stent Graft, marking a significant milestone for its MedTech portfolio in the European Union. This next-generation device is specifically designed to treat complications arising from portal hypertension in patients with cirrhosis. A key feature of the stent is its adjustable diameter, ranging from 6 to 10 mm, which allows physicians to personalize therapy during the procedure. The company expects this innovation to provide a more tailored approach to liver treatment compared to traditional fixed-diameter options. Detailed data from the pivotal ARCH clinical trial regarding the device's performance is scheduled for presentation on April 12, 2026. This regulatory approval expands BD's market reach in Europe and strengthens its position in the interventional medicine sector. While the news is positive for the company's growth prospects, it represents a specific product milestone within its broader healthcare segment.